Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2020 Dec;83(6):1704-1716.
doi: 10.1016/j.jaad.2020.09.001. Epub 2020 Sep 4.

National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1

Joel M Gelfand  1 , April W Armstrong  2 , Stacie Bell  3 , George L Anesi  4 , Andrew Blauvelt  5 , Cassandra Calabrese  6 , Erica D Dommasch  7 , Steve R Feldman  8 , Dafna Gladman  9 , Leon Kircik  10 , Mark Lebwohl  11 , Vincent Lo Re 3rd  12 , George Martin  13 , Joseph F Merola  14 , Jose U Scher  15 , Sergio Schwartzman  16 , James R Treat  17 , Abby S Van Voorhees  18 , Christoph T Ellebrecht  19 , Justine Fenner  11 , Anthony Ocon  20 , Maha N Syed  19 , Erica J Weinstein  21 , Jessica Smith  3 , George Gondo  3 , Sue Heydon  3 , Samantha Koons  3 , Christopher T Ritchlin  20
Affiliations
Practice Guideline

National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1

Joel M Gelfand et al. J Am Acad Dermatol. 2020 Dec.

Abstract

Objective: To provide guidance about management of psoriatic disease during the coronavirus disease 2019 (COVID-19) pandemic.

Study design: A task force (TF) of 18 physician voting members with expertise in dermatology, rheumatology, epidemiology, infectious diseases, and critical care was convened. The TF was supplemented by nonvoting members, which included fellows and National Psoriasis Foundation (NPF) staff. Clinical questions relevant to the psoriatic disease community were informed by questions received by the NPF. A Delphi process was conducted.

Results: The TF approved 22 guidance statements. The average of the votes was within the category of agreement for all statements. All guidance statements proposed were recommended, 9 with high consensus and 13 with moderate consensus.

Limitations: The evidence behind many guidance statements is limited in quality.

Conclusion: These statements provide guidance for the management of patients with psoriatic disease on topics ranging from how the disease and its treatments impact COVID-19 risk and outcome, how medical care can be optimized during the pandemic, what patients should do to lower their risk of getting infected with severe acute respiratory syndrome coronavirus 2 and what they should do if they develop COVID-19. The guidance is intended to be a living document that will be updated by the TF as data emerge.

Keywords: COVID-19; SARS-CoV-2; biologics; psoriasis; psoriatic arthritis.

PubMed Disclaimer

References

    1. Zhu N., Zhang D., Wang W., et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–733. - PMC - PubMed
    1. Diamond B. The renin-angiotensin system: an integrated view of lung disease and coagulopathy in COVID-19 and therapeutic implications. J Exp Med. 2020:217. - PMC - PubMed
    1. Hirano T., Murakami M. COVID-19: a new virus, but a familiar receptor and cytokine release syndrome. Immunity. 2020;52:731–733. - PMC - PubMed
    1. Matheson N.J., Lehner P.J. How does SARS-CoV-2 cause COVID-19? Science. 2020;369:510–511. - PubMed
    1. Guan W.J., Ni Z.Y., Hu Y., et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–1720. - PMC - PubMed

Publication types

MeSH terms

Substances